The new Siemens COVID-19 test assays for the spike 1 protein neutralizing antibodies, which prevents viral penetration into the cell. Targeting the specific protein gives the clinician several distinct advantages over our earlier IgG determinant. First, the specificity reduces the potential of cross-reactivity, thereby making it very sensitive to the COVID-19 and not to other coronaviruses. Second, it’s highly likely that future vaccines will be specific for the spike 1 (S1) protein inhibition which essentially prevents viral replication. Today, most vaccines are being targeted to neutralize the S1 protein. Lastly, this test will clearly show if the individual (either by having had the disease or by being vaccinated) has developed specific and long-term immunity.
>20 studies support the ability of anti-RBD to block (neutralize) infection
Is there a difference in the antibodies detected?
Feel free to contact our specialist to find out more about prices and services. We are always ready to answer your questions.
We don't just deliver results, we provide peace of mind. TM